Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(2 years from now) | |
US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(2 years from now) | |
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(5 years from now) | |
US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(5 years from now) | |
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(6 years from now) |
Eucrisa is owned by Anacor Pharms Inc.
Eucrisa contains Crisaborole.
Eucrisa has a total of 8 drug patents out of which 0 drug patents have expired.
Eucrisa was authorised for market use on 14 December, 2016.
Eucrisa is available in ointment;topical dosage forms.
Eucrisa can be used as method of treating mild to moderate atopic dermatitis..
Drug patent challenges can be filed against Eucrisa from 23 September, 2022.
The generics of Eucrisa are possible to be released after 20 July, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-191) | Apr 03, 2026 |
New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
Pediatric Exclusivity(PED) | Sep 23, 2023 |
New Patient Population(NPP) | Mar 23, 2023 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL